ORP Grant History
The NCCN Oncology Research Program (ORP) is a comprehensive program of research platforms and scientific advisors to foster the development of world-class therapies to treat people with cancer. The NCCN ORP’s core services focus on assisting companies with drug development plans and strategies, facilitating the conduct of preclinical, translational, and clinical research at NCCN Member Institutions, and ensuring that results of funded research projects are publicly disseminated. The NCCN ORP can also establish research collaborations between NCCN Member Institutions and industry in Phase IV, quality-of-life, cancer prevention, and outcomes research.
The NCCN ORP has collaborated with pharmaceutical and biotechnology companies to support investigator-initiated trials to study both FDA-approved and investigational agents/devices, to seek novel enhanced, effective, and efficient cancer therapy. In addition, the ORP is funding projects to develop new insights into cancer care delivery outcomes and quality, as well as identify solutions to barriers affecting optimal cancer management.
NCCN has worked with the following companies and compounds to support investigator-initiated research and quality improvement initiatives:
- Abraxis BioScience, Inc. – clinical studies of nab-paclitaxel
- Allos Therapeutics, Inc. – clinical studies of pralatrexate
- Astellas Scientific and Medical Affairs, Inc. – for preclinical and clinical studies of enzalutamide
- AstraZeneca Pharmaceuticals, LP – for clinical, preclinical and correlative studies of osimertinib
- AstraZeneca Pharmaceuticals, LP – quality improvement projects in non-small cell lung cancer
- AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in ovarian cancer
- AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in small cell lung cancer
- AstraZeneca Pharmaceuticals, LP – quality improvement/ projects in early stage non-small cell lung cancer
- AVEO Pharmaceuticals, Inc. – clinical studies of tivozanib
- Bayer HealthCare Pharmaceuticals, Inc. – clinical studies of sorafenib
- Boehringer Ingelheim, Pharmaceuticals, Inc. – clinical studies of afatinib
- Boehringer Ingelheim Pharmaceuticals, Inc. – clinical studies of nintedanib
- Boehringer Ingelheim Pharmaceuticals, Inc. – clinical studies of volasertib
- Boehringer Ingelheim Pharmaceuticals, Inc. – studies of combination therapies with afatinib in lung cancer
- Bristol-Myers Squibb Company and ImClone Systems Incorporated – clinical studies of cetuximab in head and neck cancers and bladder cancers
- Cephalon, Inc. – clinical studies of bendamustine
- Genentech, Inc. – mutli-institutional clinical study of carboplatin, pemetrexed, and bevaciumab, with or without atezolizumab, in lung cancer
- GlaxoSmithKline LLC – pre-clinical and clinical studies of dabrafenib
- GlaxoSmithKline LLC – clinical studies of pazopanib
- GlaxoSmithKline LLC – clinical studies of ofatumumab
- GlaxoSmithKline LLC – clinical studies of trametinib
- GlaxoSmithKline LLC – multi-institutional clinical study of trametinib in melanoma with BRAF non-V600 mutations
- ImmunoGen, Inc. – pre-clinical studies and clinical studies of mirvetuximab soravtansine (IMGN853)
- Eli Lilly and Company – pre-clinical and clinical studies of abemaciclib
- Eli Lilly and Company –quality improvement/ projects in lung and thyroid cancers
- Merck & Co., Inc. – clinical studies of vorinostat
- Onyx Pharmaceuticals, Inc. – clinical studies of carfilzomib
- Peregrine Pharmaceuticals, Inc. – clinical and correlative studies of bavituximab in combination with other therapeutic strategies for the treatment of solid tumors
- Pfizer, Inc. – clinical studies of irinotecan and celecoxib
- Pfizer, Inc. – preclinical and specialized imaging studies of sunitinib
- Pfizer, Inc. – clinical studies of axitinib
- Pfizer, Inc. – studies using components of EMBRACE
- Pfizer Global Medical Grants & Myovant Sciences – quality improvement/ projects in Prostate Cancer Patients
- Puma Biotechnology – clinical and correlative studies of neratinib
- Roche Laboratories, Inc. – clinical studies of capecitabine
- Taiho Oncology – clinical studies of trifluridine/tipiracil
- Taiho Oncology – clinical studies of futibatinib
- Taiho Oncology – clinical studies of decitabine/cedazuridine
- Wyeth – clinical studies of temsirolimus
Abemaciclib Studies
Afatinib Studies
Afatinib Combination Studies
Axitinib Studies
Bavituximab Studies
Bendamustine Studies
Capecitabine Studies
Carfilzomib Studies
Celecoxib Studies
Cetuximab Studies
Dabrafenib Studies
Decitabine/Cedazuridine Studies
EMBRACE Component Studies
Enzalutamide Studies
Futibatinib Studies
Irinotecan Studies
Mirvetuximab Soravtansine (Preclinical)
Mirvetuximab Soravtansine (Clinical)
nab-Paclitaxel Studies
Neratinib Studies
Nintedanib Studies
Ofatumumab Studies
Osimertinib Studies
Pazopanib Studies
Pralatrexate Studies
Quality Improvement Studies – Lung
Quality Improvement Studies – Lung (Early Stage)
Quality Improvement Studies – Lung (Small Cell)
Quality Improvement Studies – Lung & Thyroid
Quality Improvement Studies – Ovarian
Quality Improvement Studies – Prostate
Sorafenib Studies
Sunitinib Studies (Preclinical)
Sunitinib Studies (Specialized Imaging)
Temsirolimus Studies
Tivozanib Studies
Trametinib Multi-site Clinical Study
Trametinib Studies
Trifluridine/Tipiracil Studies
Vorinostat Studies
Abemaciclib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Seth A. Wander, MD, PhD | Massachusetts General Hospital Cancer Center | A Prospective, Multi-Center, Biomarker Driven Trial to Evaluate the Efficacy and Safety of Abemaciclib Monotherapy Beyond First Line CDK4/6 Inhibition in ER + Breast Cancer (AMBER) |
| Mathew Cherian, MBBS | The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute | Refractory Hormone Receptor Positive Breast Cancer: A Role for Estrogen Receptor β |
| Inan Olmez, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | A Preclinical Study of Abemaciclib in Combination with Merestinib against Breast Cancer Brain Metastases |
| Shunqiang Li, PhD | Washington University in St. Louis | Inhibition of Aurora A Kinase Restores Sensitivity to CDK 4/6 Blockade of ER Positive Breast Cancers |
| Chenbo Zeng, PhD | Abramson Cancer Center at the University of Pennsylvania | PET Imaging of Cell Cycle Arrest for Predicting Response to Abemaciclib Alone or in Combination with Endocrine Therapy |
Afatinib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Christine Chung, MD/Jill Gilbert, MD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/Vanderbilt-Ingram Cancer Center | Phase I/II Study of Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed by Standard Chemoradiation in HPV Negative or High-Risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC Patients |
| Danielle Margalit, MD, MPH | Dana-Farber/Brigham and Women’s Cancer Center | Phase I Study of Afatinib with Postoperative Radiation Therapy for Intermediate and High Risk Squamous Cancer of the Head and Neck (SCCHN) |
| David G. Pfister, MD | Memorial Sloan Kettering Cancer Center | Phase I Study of Induction Chemotherapy with Afatinib, Ribavirin, and Weekly Carboplatin/Paclitaxel for Stage IVA/IVB HPV Associated Oropharynx Squamous Cell Cancer (OPSCC) |
| Lecia Sequist, MD, MPH | Massachusetts General Hospital Cancer Center | Randomized Phase II Study Comparing Concise (3 months) versus Prolonged (2 years) Afatinib as Adjuvant Therapy for Patients with Resected Stage I-III NSCLC with EGFR Mutation |
Afatinib Combination Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Aarti Bhatia, MD, MPH | Yale Cancer Center/Smilow Cancer Hospital | Single-Arm Phase II trial of Dual Inhibition of EGFR with Afatinib and Cetuximab with Correlative Studies in the Second-Line Treatment of Recurrent or Metastatic Squamous Cell Cancers of the Head and Neck |
| Michael Gibson, MD, PhD | Vanderbilt-Ingram Cancer Center | Afatinib and Nivolumab as Treatment of Platinum- and Cetuximab-Refractory Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Sally York, MD | Vanderbilt-Ingram Cancer Center | Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired Resistance to First or Third Generation EGFR TKIs |
Axitinib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Alan L. Ho, MD, PhD | Memorial Sloan Kettering Cancer Center | A Phase II Study of Axitinib (AG-013736) in Patients with Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma |
| Mateusz Opyrchal, MD, PhD | Roswell Park Comprehensive Cancer Center | Predictive Markers of Response in a Phase II Trial of Axitinib in Advanced Melanoma |
| Jonathan Strosberg, MD/Emily Bergsland, MD | Moffitt Cancer Center/ UCSF Helen Diller Family Comprehensive Cancer Center | A Phase II Study of Axitinib in Advanced Carcinoid Tumors |
| Francis P. Worden, MD | University of Michigan Comprehensive Cancer Center | Phase II Trial Evaluating Axitinib in Patients with Unresectable, Recurrent or Metastatic Head and Neck Cancer |
| Paul Swiecicki, MD | University of Michigan Comprehensive Cancer Center | Phase II Expansion Trial Evaluating Axitinib in Patients with Unresectable Recurrent, or Metastatic Head and Neck Cancer utilizing Choi Response |
Bavituximab Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Jessica Frakes, MD | Moffitt Cancer Center | A Phase I trial of Sorafenib and Bavituximab plus Stereotactic Body Radiation Therapy (SBRT) for 1st Line Treatment of Unresectable Hepatocellular Carcinoma |
| Elizabeth Gerstner, MD | Massachusetts General Hospital Cancer Center | Phase II Clinical Trial of Bavituximab with Radiation and Temozolomide for Patients with Newly Diagnosed Glioblastoma |
| Ranee Mehra, MD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 Study of Pembrolizumab and Bavituximab for Progressive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck |
Bendamustine Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Marc C. Chamberlain, MD | University of Washington | A Phase II Study of Bendamustine (Cephalon, Inc.) in the Treatment of Recurrent High-Grade Gliomas (Anaplastic Gliomas and Glioblastoma) |
| John C. Grecula, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | Phase I Study of Bendamustine and Fractionated Stereotactic Radiotherapy (SRT) for Patients with 1-4 Brain Metastases from Solid Malignancies |
| Rachel M. Layman, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | Phase I/II Study of Bendamustine and Erlotinib for Metastatic or Locally Advanced Triple Negative Breast Cancer |
| Edward Pan, MD | Moffitt Cancer Center | Phase I Study of Bendamustine with Concurrent Whole Brain Radiation Therapy in Patients with Brain Metastases from Solid Tumors |
| Francisco Robert, MD/Rodolfo Bordoni, MD | O'Neal Comprehensive Cancer Center at UAB/Georgia Cancer Specialists | Phase I/IIa Study of the Novel Combination of Bendamustine with Irinotecan Followed by Etoposide/Carboplatin in Chemonaive Patients with Extensive Stage Small Cell Lung Cancer |
| Apostolia-Maria Tsimberidou, MD, PhD | The University of Texas MD Anderson Cancer Center | A Phase I Study of Bendamustine and Bevacizumab for Patients with Advanced Cancers |
Capecitabine Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Tanios Bekaii-Saab, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients with Advanced Pancreatic Cancer |
| Renuka Iyer, MD | Roswell Park Comprehensive Cancer Center | Multicenter, Open Label, Phase II Clinical Study of Gemcitabine, Capecitabine and Avastin in Pancreatic Cancer |
| Nikhil Khushalani, MD | Roswell Park Comprehensive Cancer Center | Phase II Study of Capecitabine in Combination with Oxaliplatin and Radiotherapy for Esophageal and Gastroesophageal Junction Cancer |
| Andrew Ko, MD/Kimberly Jones, MD | UCSF Helen Diller Family Comprehensive Cancer Center/Huntsman Cancer Institute at the University of Utah | A Phase I Study, with expanded cohort, of Biweekly Fixed-Dose Rate Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic and Biliary Carcinomas |
| Daniel Laheru, MD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Thymidylate Synthase (TS) Genotype-Directed Phase II Trial of Oral Capecitabine for 2nd Line Treatment of Advanced Pancreatic Cancer |
| Mary Mulcahy, MD | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | A Phase II Study of Capecitabine and Oxaliplatin with Radiation for Esophageal and Gastroesophageal Junction Adenocarcinoma |
| Lakshmi Pendyala, PhD | Roswell Park Comprehensive Cancer Center | Gene Expression Profiling of Esophageal Cancer in Patients Receiving Oxaliplatin, Capecitabine and Radiation, Exploring Correlations to Response |
| M. Wasif Saif, MD, MBBS | Yale University School of Medicine | A Phase I/II, Open-Label, Dose Escalation, Safety and Efficacy Study of PHY906 Plus Capecitabine in Patients with Advanced Pancreatic Carcinoma |
| Hope Uronis, MD | Duke Cancer Institute | Correlative Biomarker Proposal for A Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinoma |
| Robert Warren, MD | UCSF Helen Diller Family Comprehensive Cancer Center | A Retrospective Analysis of Thymidylate Synthase (TS) and Thymidine Phosphorylase (TP) Levels and Thymidylate Synthase (TS) Genetic Polymorphisms from Archived Hepatocellular Carcinoma (HCC) Surgical Specimens |
Carfilzomib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Jeremy Abramson, MD, MMSc | Massachusetts General Hospital Cancer Center | Phase I Study of Carfilzomib Plus Belinostat in Relapsed/Refractory non-Hodgkin Lymphoma Subtypes |
| Charalambos Andreadis, MD, MSCE | UCSF Helen Diller Family Comprehensive Cancer Center | A Phase Ib Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory non-Hodgkin Lymphoma |
| Steven Horwitz, MD | Memorial Sloan Kettering Cancer Center | A Phase Ib/IIa Study of Combination Therapy with Carfilzomib, Romidepsin, Lenalidomide in Patients with Relapsed or Refractory B- and T-cell Lymphomas |
| Stephen Smith, MD | Fred Hutchinson Cancer Research Center | A Response-Adapted Clinical Trial of Weekly Carfilzomib with or without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma |
Celecoxib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Manuel Hidalgo, MD, PhD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Biological Evaluation of Celecoxib in Pancreatic Cancer |
| Milind Javle, MD | Roswell Park Comprehensive Cancer Center | Celecoxib in Combination with Irinotecan (CPT-11), 5-Fluorouracil and Leucovorin in Patients with Advanced Cancer: A Phase I Study |
| Ritsuko Komaki, MD, FACR | The University of Texas MD Anderson Cancer Center | A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib with Radiation Therapy for Patients with Unresectable Non-Small Cell Lung Cancer (NSCLC) |
| Nancy Lewis, MD | Fox Chase Cancer Center | A Randomized Trial of Celecoxib +/- Rosiglitazone vs. Placebo in Patients with Early Stage Non-Invasive Bladder Carcinoma |
| Brian Rini, MD | UCSF Helen Diller Family Comprehensive Cancer Center | A Phase II Trial of Celecoxib Plus Interferon-Alpha in Advanced Renal Cell Carcinoma |
| Manisha Shah, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | Phase II Study of Celecoxib in Metastatic Differentiated Thyroid Carcinoma |
| Charles Shapiro, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | A Phase II Trial of Exemestane (Aromasin) in Combination with Celecoxib (Celebrex) as Neoadjuvant Treatment in Postmenopausal Women with Stage II, III, and IV Breast Cancer |
| Przemyslaw Twardowski, MD | City of Hope National Medical Center | Biologic Markers of Angiogenesis: A Companion Study to Phase I Trial of Oral Etoposide in Combination with Celecoxib in Patients with Advanced Malignancies and Phase I Trial of Oral Cyclophosphamide in Combination with Celecoxib in Patients with Advanced Malignancies |
Cetuximab Studies
| COORDINATING CENTER/PROJECT CHAIR | PARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR | STUDY |
|---|---|---|
| University of Michigan Comprehensive Cancer Center/Maha Hussain, MD, FACP | City of Hope National Medical Center/Przemyslaw Twardowski, MD | Phase II Randomized Trial of Gemcitabine and Cisplatin with or without Cetuximab in Patients with Urothelial Carcinoma |
| Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD | ||
| Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance/Evan Yu, MD | ||
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/Mario Eisenberger, MD | ||
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Gary MacVicar, MD | ||
| Roswell Park Comprehensive Cancer Center/Ellis Levine, MD | ||
| Stanford Cancer Institute/Sandy Srinivas, MD | ||
| The University of Texas MD Anderson Cancer Center/Arlene Siefker-Radtke, MD | ||
| Vanderbilt-Ingram Cancer Center/Igor Puzanov, MD | ||
| PARTICIPATING NON-MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR | ||
| Boston Medical Center/Gretchen Gignac, MD | ||
| Lahey Clinic/Christopher Tretter, MD | ||
| University of Southern California/David I. Quinn, MBBS, PhD, FRACP | ||
| Wayne State University/Karmanos Cancer Institute/Ulka Vaishampayan, MD | ||
| Memorial Sloan Kettering Cancer Center/Matthew Fury, MD, PhD | City of Hope National Medical Center/Dean Lim, MD | A Phase II Randomized Study of Cetuximab at Either 500 or 750 mg/m2 Every Other Week for Recurrent or Metastatic Head and Neck Squamous Cell Cancer |
| Fox Chase Cancer Center/Ranee Mehra, MD | ||
| Huntsman Cancer Institute at the University of Utah/Neeraj Agarwal, MD | ||
| Robert H. Lurie Comprehensive Cancer Center of Northwestern University/Bruce Brockstein, MD | ||
| Moffitt Cancer Center/Tawee Tanvetyanon, MD | ||
| University of Tennessee Cancer Institute/Furhan Yunus, MD | ||
| Fred & Pamela Buffett Cancer Center/Sandeep Rajan, MD |
Dabrafenib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Paul Chapman, MD | Memorial Sloan Kettering Cancer Center | Adjuvant Therapy of Stage IIIC BRAF-mutated Melanoma Patients with GSK2118436 |
| Mark Kelley, MD, MMHC, FACS | Vanderbilt-Ingram Cancer Center | Biomarkers of Response and Resistance to Sequential B-RAF and MEK Targeted Therapy in a Pre-surgical Model of Advanced, Operable Melanoma |
| Martin McMahon, PhD | UCSF Helen Diller Family Comprehensive Cancer Center | Mechanisms of BRAF (V600E) Inhibitor Sensitivity or Resistance in Genetically Engineered Mouse Models of Malignant Melanoma |
| Manisha Shah, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | A Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-mutated Advanced Malignant Solid Tumors |
| Manisha Shah, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | A Randomized Phase 2 Study of Single Agent GSK2118436 (BRAFi) vs Combination Regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in Patients with BRAF Mutated Thyroid Carcinoma |
Decitabine/Cedazuridine Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Michael Byrne, DO | Vanderbilt Ingram Cancer Institute | Phase 2 Study of Decitabine and Cedazuridine in Combination with Venetoclax for AML Relapse after Allogenic Hematopoietic Cell Transplantation |
| Gurkamal Chatta, MD | Roswell Park Comprehensive Cancer Center | A Phase IB Clinical Trial: Improving Outcomes with Androgen Pathway Inhibitors by targeting DNA methyltransferase Activity |
| Martin D. McCarter, MD | University of Colorado Anschutz Medical Campus | Oral Decitabine/Cedazuridine (Invoqi) in Combination with Nivolumab as a Strategy to Enhance the Efficacy of Immune Checkpoint Blockade in Unresectable or Metastatic Mucosal Melanoma |
EMBRACE Component Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Nancy Lin, MD | Dana-Farber Cancer Institute | The EMBRACE Program: A Comprehensive Approach to Improve the Care of Patients with Metastatic Breast Cancer |
| Laura Spring, MD | Massachusetts General Hospital Cancer Center | Expanding Precision Medicine for Patients with Metastatic Breast Cancer in the Community: Leveraging Academic Strength and Community Partnership |
| Aki Morikawa, MD, PhD | University of Michigan Rogel Cancer Center | Personalized Multi-Care: A Tailored Approach to multidisciplinary care coordination delivery for metastatic breast cancer patients with central nervous system metastases |
| Erin Gillespie, MD & Allison Lipitz-Snyderman, PhD | Memorial Sloan Kettering Cancer Center | Leveraging an Academic-Community Partnership Model to Improve the Quality of Radiation Treatment for Metastatic Breast Cancer Patients |
| Karen Lisa Smith, MD, MPH | Johns Hopkins University | The Johns Hopkins Metastatic Breast Cancer Partners Program: Collaborating to Improve Metastatic Breast Cancer Care |
Enzalutamide Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Helen Chamberlin, PhD | The Ohio State University Comprehensive Cancer Center –James Cancer Hospital and Solove Research Institute | Evaluating the Efficacy of Enzalutamide Therapy in Preventing Tumor Progression in a Preclinical Mouse Model of Type 1 Endometrial Carcinoma |
| Ajay Gopal, MD | Fred Hutchinson Cancer Research Center/ University of Washington/Seattle Cancer Care Alliance | Androgen Receptor Targeting in Mantle Cell Lymphoma: A Pilot Trial of Enzalutamide |
| James Harding, MD | Memorial Sloan Kettering Cancer Center | A Multi-Center Phase I/IB Study of Enzalutamide with and without Sorafenib in Advanced Hepatocellular Carcinoma Patients |
| Hao G. Nguyen, MD, PhD | UCSF Helen Diller Family Comprehensive Cancer Center | Phase II Trial of Definitive Radiotherapy with Leuprolide and Enzalutamide in High Risk Prostate Cancer |
| Shannon Westin, MD, MPH | The University of Texas MD Anderson Cancer Center | A Phase II study with a Limited Safety Lead-In of Enzalutamide in Combination with Carboplatin and Paclitaxel in Advanced Stage or Recurrent Endometrial Cancer |
Futibatinib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Jordi Rodon Ahnert, MD, PhD | The University of Texas MD Anderson Cancer Center | Phase Ib trial of Olaparib in Combination with Futibatinib in All Solid Tumors with BRCA1/2 Alterations |
| Siqing Fu, MD, PhD | The University of Texas MD Anderson Cancer Center | A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma |
| S. Roychowdhury, MD, PhD | The Ohio State University CCC - James Cancer Hospital and Solove Research Institute | Developing Futibatinib for Use on Novel FGFR Genomic Alterations and in Therapy Combination |
| Nguyen Hoai Tran, MD | Mayo Clinic Cancer Center | Phase 2 Study of FRFR4 Inhibitor Futibatinib in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Advanced or Metastatic Hepatocellular Carcinoma with FGF19 Expression after First-line Therapy |
Irinotecan Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Patrick J. Creaven, MD, PhD | Roswell Park Comprehensive Cancer Center | Phase I Study of Irinotecan followed by Capecitabine in Patients with Advanced Breast Carcinoma |
| Stacy Moulder, MD | Moffitt Cancer Center | A Single Arm Phase II Study of Gemcitabine and Irinotecan in Patients with Metastatic Breast Cancer |
| Pedro Ramirez, MD | The University of Texas MD Anderson Cancer Center | Phase I Trial of Concurrent Weekly CPT-11, Cisplatinum, and Radiotherapy for Patients with Newly Diagnosed Stage IIIb-IVa Cancer of the Uterine Cervix |
| M. Wasif Saif, MD, MBBS | O'Neal Comprehensive Cancer Center at UAB | A Phase I and Pharmacologic Trial of Sequential Administration of Bi-weekly Gemcitabine as a 24-hour IV Infusion followed by Irinotecan as a 24-hour IV Infusion in Adult Cancer Patients |
| Charles Shapiro, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | Phase II Study of Sequentially Administered Mitomycin and Irinotecan in Patients with Refractory Metastatic and Inflammatory Breast Cancers |
Mirvetuximab Soravtansine (Preclinical)
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Michael Birrer, MD, PhD | Massachusetts General Hospital | Mechanisms of Sensitivity and Resistance to Mirvetuximab Soravtansine: Ovarian Cancer and Mesothelioma |
| Michael Birrer, MD, PhD | O'Neal Comprehensive Cancer Center at UAB | Mechanisms of Sensitivity and Resistance to Mirvetuximab Soravtansine: Ovarian Cancer and Mesothelioma |
| Analisa DiFeo, PhD | Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute | Identifying Susceptibilities and Candidate Pharmacodynamic Biomarkers for Mirvetuximab Soravtansine in High-Grade Ovarian and Endometrial Cancer |
| John Hays, MD, PhD | The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Solove Research Institute | Regulation of Folate Receptor Alpha Expression and Mirvetuximab Soravtansine Sensitivity in Endometrial Cancer through Selective Modulation of Estrogen Receptor |
| Kian-Huat Lim, MD | Siteman Cancer Center at Barnes-Jewish Hospital and Washing University School of Medicine | 89Zr-DFO Labeling of M9346A to Further Characterize the Biology and Efficacy of Mirvetuximab Soravtansine in Animal Models for Future Clinical Applications |
| Yunfei Wen, PhD | The University of Texas MD Anderson Cancer Center | Promoting Autophagic Cell Death in High-Grade Serous Ovarian Cancer by Mirvetuximab Soravtansine |
Mirvetuximab Soravtansine (Clinical)
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Kimberly Blackwell, MD | Duke Cancer Institute | Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-expressing, Triple Negative Breast Cancer (TNBC) with Residual Disease post Standard Neoadjuvant Chemotherapy |
| Mihaela Cristea, MD | City of Hope National Medical Center | A Phase I Dose-Escalation Safety and Tolerability Study of Mirvetuximab Soravtansine (IMGN853) and Gemcitabine in Patients with FRα-positive Recurrent Ovarian, Primary Peritoneal, Fallopian tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC) |
| Stacey Moulder, MD, MSCI | The University of Texas MD Anderson Cancer Center | Women’s Triple-Negative First-Line Study: A Phase II Trial of Mirvetuximab Soravtansine in Patients with Localized Triple-Negative Breast Cancer (TNBC) with Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy (NACT), including a Lead in Cohort to Establish Activity in Patients with Metastatic TNBC |
nab-Paclitaxel Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Mihaela Cristea, MD | City of Hope National Medical Center | Phase I Trial of Intraperitoneal nab-paclitaxel (Abraxane®) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity |
| Grace Dy, MD | Roswell Park Comprehensive Cancer Center | SPARC Expression in NSCLC is Correlated with Response to nab-paclitaxel |
| Siqing Fu, MD | The University of Texas MD Anderson Cancer Center | Phase I Trial of Hepatic Arterial Infusion of Abraxane with a Pharmacokinetic Study in Advanced Solid Cancer Patients with Predominant Hepatic Metastases |
| Matthew G. Fury, MD, PhD | Memorial Sloan Kettering Cancer Center | Phase I Study of Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane®) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients with Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC) |
| Thomas Olencki, DO | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | A Phase 2 Study of Weekly Infusion nab-paclitaxel (paclitaxel protein-bound particles for injectable suspension) in Patients with Unresectable and Metastatic Uveal Melanoma |
| Gregory A. Otterson, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | Phase II Trial of Abraxane plus Carboplatin for Advanced NSCLC for Patients at Risk of Bleeding from VEGF Directed Therapies |
| Jasgit Sachdev, MD | University of Tennessee Cancer Institute | Neoadjuvant Weekly nab-paclitaxel (Abraxane®) Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide with Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple Negative Invasive Breast Cancer |
Neratinib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Rutika Mehta, MD, PhD | Moffitt Cancer Center | A Phase II Study Of Neratinib In Combination With Chemotherapy And Trastuzumab In HER2 Overexpressing Gastroesophageal Cancers |
| Scott Plotkin, MD, PhD | Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center | Phase 2 study of neratinib for adolescents and adults with neurofibromatosis 2 and progressive NF2-related neoplasms: a sub-study of the INTUITT-NF2 platform-basket trial (NCT04374305) |
| Namrata Vijayvergia, MD | Fox Chase Cancer Center | A Multi-Center Phase I trial of Neratinib and fam-trastuzumab deruxtecan in advanced refractory gastric cancer patients |
Nintedanib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Patrick Boland, MD | Roswell Park Comprehensive Cancer Center | A Phase I/II Study of Nintedanib and Capecitabine in Refractory Metastatic Colorectal Cancer |
| Grace Dy, MD | Roswell Park Comprehensive Cancer Center | A Phase II Randomized Study Evaluating Nintedanib versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing ChemoRadiation Therapy |
| Ramaswamy Govindan, MD | Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | A Pilot Study of Nintedanib in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Renuka Iyer, MD | Roswell Park Comprehensive Cancer Center | Multicenter Phase 2 Trial of Nintedanib (BIBF 1120) in Patients with Carcinoid Tumors |
Ofatumumab Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Seema Bhat, MD | Roswell Park Comprehensive Cancer Center | A Multicenter Phase II Study of Ofatumumab and Bortezomib (OB) in Previously Untreated Patients With Waldenstrom Macroglobulinemia |
| Jennifer Brown, MD, PhD | Dana-Farber Cancer Institute | Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL |
| Alessandra Ferrajoli, MD | The University of Texas MD Anderson Cancer Center | Phase II Study of Ofatumumab as front-line treatment in elderly, unfit patients with Chronic Lymphocytic Leukemia (CLL) |
| Francisco Hernandez-Ilizaturri, MD | Roswell Park Comprehensive Cancer Center | Ofatumumab (O) in Combination with Chemotherapy: Hyper-Fractionated Cyclophosphamide, Doxorubicin, Vincristine and Dexamethasone (O-HyperCVAD) Alternating with Ofatumumab High-Dose Cytarabine and Methotrexate (O-MA) for Patients With Newly Diagnosed Mantle Cell Lymphoma |
| Shuo Ma, MD, PhD | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | Correlative Studies in Conjunction with A Phase II Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia |
Osimertinib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Daniel Gomez, MD | The University of Texas MD Anderson Cancer Center | Randomized Phase II Trial of Osimertinib with or without Local Consolidation Therapy (LCT) for Patients with EGFR-mutant Metastatic NSCLC (NORTHSTAR) |
| Pasi Janne, MD, PhD | Dana-Farber/Brigham and Women's Cancer Center/ Massachusetts General Hospital Cancer Center | A Phase 2 Study of Osimertinib in Combination with Selumetinib in EGFR Inhibitor Naïve Advanced EGFR Mutant Lung Cancer |
Pazopanib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Nilofer S. Azad, MD/Vivek Subbiah, MD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins/The University of Texas MD Anderson Cancer Center | A Phase I Study Determining the Safety and Tolerability of Combination Therapy with Pazopanib, a VEGFR/PDGFR/Raf Inhibitor, and GSK 1120212, a MEK Inhibitor, in Advanced Solid Tumors Enriched with Patients with Advanced Differentiated Thyroid Cancer, Soft Tissue Sarcoma, and Cholangiocarcinoma |
| Laura QM Chow, MD | University of Washington/Seattle Cancer Care Alliance | A Phase I Clinical Trial of Pazopanib in Combination with Escalating Doses of Radioactive 131I in Patients with Well-Differentiated Thyroid Carcinoma Refractory to Radioiodine, Despite Having Some Uptake |
| David Hong, MD | The University of Texas MD Anderson Cancer Center | Phase I Combination of Pazopanib and Everolimus in PI3KCA Mutation Positive/PTEN Loss Patients with Advanced Solid Tumors Refractory to Standard Therapy |
| Herbert I. Hurwitz, MD | Duke Cancer Institute | Phase I Dose Escalation of Pazopanib Plus TH302 in Advanced Solid Tumors |
| Sheetal Kircher, MD | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumor (PNET) |
| William D. Tap, MD | Memorial Sloan Kettering Cancer Center | A Phase IB/II Study of Gemcitabine and Docetaxel in Combination with Pazopanib (gem/doce/pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS) |
| Margaret von Mehren, MD | Fox Chase Cancer Center | Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma |
Pralatrexate Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Tanios Bekaii-Saab, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | Phase II Study of Pralatrexate and Docetaxel in Patients with Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-Based Therapy |
| Patrick Boland, MD | Roswell Park Comprehensive Cancer Center | Pralatrexate in Combination with Oxaliplatin in Advanced Esophago-Gastric Cancer: A Phase II Trial with Predictive Molecular Correlates |
| Marcela G. del Carmen, MD, MPH | Massachusetts General Hospital Cancer Center | Phase I/II Study of Carboplatin and Pralatrexate in Patients with Recurrent Platinum Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer |
| Jean L. Grem, MD | Fred & Pamela Buffett Cancer Center | A Phase I Clinical Trial of Sequential Pralatrexate Followed by a 48-Hour Infusion of 5-Fluorouracil Given Every Other Week in Adult Patients with Solid Tumors |
| Alan L. Ho, MD, PhD | Memorial Sloan Kettering Cancer Center | A Multi-Institution Phase II Study of Pralatrexate with Vitamin B12 and Folic Acid Supplementation for Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) |
| Michaela Liedtke, MD | Stanford Cancer Institute | A Phase I Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma |
Quality Improvement Studies - Lung
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Charu Aggarwal, MD | Hospital of the University of Pennsylvania (HUP) and University of Pennsylvania Health System (UPHS) Community Based Hospitals | System-wide integration of plasma-based next generation sequencing into clinical pathways for detection of NCCN recommended biomarkers to improve the management of patients with metastatic non-squamous NSCLC |
| Debora Bruno, MD, MS and Navid Sadri, MD, PhD | University Hospitals – Seidman Cancer Center (UH/SCC) | Developing a PREcision meDICine Thoracic (PREDICT) Service in a large practice network: focus on implementation, physician and patient impact |
| Jennifer Temel, MD and Joseph Greer, PhD | Massachusetts General Hospital Cancer Center & Affiliate Hospitals | Randomized Trial of a Supportive Care Mobile Application (App) to Improve Symptoms, Coping, and Quality of Life in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) |
Quality Improvement Studies - Lung (Early Stage)
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Katharine Rendle, PhD, MSW, MPH and Anil Vachani, MD, MS | Abramson Cancer Center at the University of Pennsylvania | Increasing Equitable Adherence to Annual Lung Cancer Screening and Diagnostic Follow-up |
| Mary E. Cooley, PhD, RN, FAAN and Michael J. Healey, MD | Dana-Farber/Brigham and Women’s Cancer Center/ Massachusetts General Hospital Cancer Center | Optimizing the Process and Uptake of Lung Cancer Screening Among Patients, Providers, and Across the Health Care System |
| Anurag K. Singh, MD, Sai Yendamuri, MD and Elizabeth Bouchard, PhD | Roswell Park Comprehensive Cancer Center | Utilizing Patient Reported Quality of Life to Inform Patient Decision Making in Early Stage Lung Cancer |
| Dan J. Raz, MD | City of Hope National Medical Center | Implementing an Early Lung Cancer Detection and Navigation Program in the Antelope Valley: Improving Access, Utilization and Outcomes in an Underserved Population |
| Elyse R. Park, PhD, MPH | Dana-Farber/Brigham and Women’s Cancer Center/Massachusetts General Hospital Cancer Center | Assessing the Impact of Health Beliefs and Psychological Factors on Lung Screening and Intentions in Urban and Rural Settings Affected by COVID |
| David Odell, MD, MMSC, FACS and Nisha Mohindra, MD, MS | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | A User-Centered Approach to Improve Treatment Outcomes in Early Stage Lung Cancer |
Quality Improvement Studies - Lung (Small Cell)
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Asrar AlAhmadi, MD | The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute | A Retrospective Study to Evaluate Disparities Among Patients with Lung Cancer Treated at a Comprehensive Cancer Center |
| Afshin Dowlati, MD / Melinda Hsu, MD | Fred Hutchinson Cancer Center | Provider and Intervention Barriers to Multidisciplinary, Guideline Concordant Care in Small Cell Lung Cancer |
| Salene M.W. Jones, PhD | Fred Hutchinson Cancer Center | Provider and Intervention Barriers to Multidisciplinary, Guideline Concordant Care in Small Cell Lung Cancer |
Quality Improvement Studies – Lung & Thyroid
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Waddah Arafat, MD | UT Southwestern Simmons Comprehensive Cancer Center | Harnessing an Electronic Health Record Based Genomics Module to Guide Clinical Decisions for Non-Small Cell Lung Cancer Care (NSCLC) |
| Grace Dy, MD | Roswell Park Comprehensive Cancer Center | PROJECT IOTA: Multidisciplinary workflow optimization to overcome challenges in biomarker testing and to expedite biomarker-based treatment decisions for patients with NSCLC. |
| John Strickler, MD | Duke Cancer Institute and Community Hospitals | Expansion of the Duke Molecular Tumor Board to community oncology sites across the Southeast to support adoption of comprehensive genomic profiling and biomarker driven therapy selection for lung and thyroid cancer patients |
| Cristina P. Rodriguez, MD | University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance | Streamlining Molecular Profiling of Thyroid Malignancies in an Academic Tertiary Referral Oncology Center and its Community Satellite Clinics |
Quality Improvement Studies - Ovarian
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Alexi A Wright, MD, MPH, Hanneke Poort, PhD, Joanna J Arch, PhD | Dana-Farber Cancer Institute, Abramson Cancer Center at the University of Pennsylvania, University of Colorado Boulder, Colorado Cancer Center | REVITALIZE: A Telehealth Intervention for Women with Advanced Ovarian Cancer and PARP Inhibitor-Related Fatigue |
| Haller J. Smith, MD | University of Alabama at Birmingham | Feasibility and impact of a comprehensive telehealth program on reducing geographic barriers to treatment and improving symptom management in rural patients with advanced ovarian cancer |
| Cary Gross, MD | Yale Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center and Smilow Cancer Hospital | CommunityRx-Cancer: An IT-enhanced patient navigation program for social determinants of health in advanced ovarian cancer |
| Barbara Goff, MD, and Donna L Berry, PhD, RN, AOCN | Fred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance | Patient-centered Education and Support for Women with Advanced Ovarian Cancer |
Quality Improvement Studies - Prostate
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Zhaoping Li, MD, PhD | The Regents of the University of California, Los Angeles | Contribution of Race to Nutritional Approach to lower Cardiovascular Risk Factors in Men undergoing Androgen Deprivation Therapy |
| Alicia Morgans, MD, MPH | Dana Farber Cancer Institute | CV CARE: CardioVascular Care of Androgen Related Effects in Prostate Cancer Patients |
| Vivek Narayan, MD, MSCE | University of Pennsylvania, Abramson Cancer Center | The Cardiovascular Risk Evaluation in Men with Prostate Cancer Study (CARE-PC): Pilot Feasibility Study to Assess Patient Awareness and Risk Mitigation |
| Camille Ragin, PhD & Daniel Geynisman, MD | Fox Chase Cancer Center | Investigating the role of African genetic ancestry in cardiovascular complications and cardiotoxicity among prostate cancer patients post treatment with androgen deprivation therapy |
| Balaji Tamarappoo, MD, PhD | Indiana University of Medicine | Personalized medical treatment of coronary atherosclerosis in prostate cancer patients guided by plaque assessment with quantitative coronary CT angiography |
Sorafenib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Ghassan K. Abou-Alfa, MD | Memorial Sloan Kettering Cancer Center | Evaluation of Pre- and Post-Treatment pERK and Ask-1 as Part of a Phase II Study of Sorafenib plus Doxorubicin Combination Therapy in Patients with Advanced Hepatocellular Carcinoma with Disease Progression on Initial Sorafenib |
| Matthew Old, MD | The Ohio State University Comprehensive Cancer Center – James Cancer Hospital And Solove Research Institute | Phase I/II Clinical Trial of Sorafenib in Combination with Cisplatin and Docetaxel in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) |
| Yasmin Thanavala, PhD | Roswell Park Comprehensive Cancer Center | Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC |
Sunitinib Studies (Preclinical)
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Long Dang, MD, PhD | University of Michigan Comprehensive Cancer Center | Targeting Tumor Reactive Response to Antiangiogenic Therapy |
| Frank Fitzpatrick, PhD | Huntsman Cancer Institute at the University of Utah | Molecular Determinants of Sunitinib Efficacy |
| Roberto Pili, MD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Vertical Inhibition of the VEGF Pathway with Sunitinib in Combination with HDAC and mTOR Inhibitors in Renal Cell Carcinoma Models |
| Sabina Signoretti, MD and James Mier, MD | Dana-Farber/Brigham and Women's Cancer Center | Massachusetts General Hospital Cancer Center | Therapy of Renal Cell Carcinoma with Sutent: Mechanism of Acquired Resistance |
| John Sunwoo, MD, FACS | Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | Preclinical Evaluation of Sunitinib in Squamous Cell Carcinoma of the Head and Neck |
| Michael Wong, MD, PhD, FRCPC | Roswell Park Comprehensive Cancer Center | Inhibition of Human Angiosarcoma and Reversal of Chemoresistance by Sunitinib |
| Sam Yoon, MD | Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center | Sunitinib with and without Radiation Therapy: Analysis in a Novel Mouse Model of Soft Tissue Sarcomas |
Sunitinib Studies (Specialized Imaging)
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| John Hoffman, MD | Huntsman Cancer Institute at the University of Utah | Sunitinib for Metastatic Renal Cell Cancer with Imaging Biomarker Assessments for the Early Prediction of Tumor Response |
| Robert G. Maki, MD, PhD | Memorial Sloan Kettering Cancer Center | 18FDG-PET As a Means to Determine Clinical Response in Soft Tissue Sarcomas in Patients Receiving a Continuous Daily Dosing Schedule of Sunitinib |
| Andrew Quon, MD | Stanford Cancer Institute | Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI |
| Jennifer Specht, MD | Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance | DCE-MRI and FDG-PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy |
Temsirolimus Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Andrew Armstrong, MD, ScM | Duke Cancer Institute | Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men with Castration Resistant Metastatic Prostate Cancer |
| Susana M. Campos, MD, MPH | Dana-Farber/Brigham and Women's Cancer Center | A Phase I/IB Study of AZD2171 (Cediranib) and Temsirolimus in Patients with Advanced Gynecological Malignancies |
| Sarat Chandarlapaty, MD, PhD | Memorial Sloan Kettering Cancer Center | A Phase I/II Trial of Temsirolimus plus Neratinib in Patients with Metastatic HER2-Amplified or Triple- negative Breast Cancer |
| Warren A. Chow, MD | City of Hope National Medical Center | Randomized, Phase II Trial of AZD6244 alone and AZD6244 plus Temsirolimus for Soft Tissue Sarcomas |
| Ira Dunkel, MD | Memorial Sloan Kettering Cancer Center | Phase I Study of Perifosine with Temsirolimus for Recurrent Pediatric Solid Tumors |
| R. Kate Kelley, MD/Sheetal Kircher, MD | UCSF Helen Diller Family Comprehensive Cancer Center/Robert H. Lurie Comprehensive Cancer Center of Northwestern University | A Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma |
| David Loeb, MD, PhD | The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase I/II Trial of Torisel® and Liposomal Doxorubicin in Patients with Advanced Soft Tissue and Bone Sarcomas |
| David Pfister, MD | Memorial Sloan Kettering Cancer Center | A Phase I/II Study of Temsirolimus + Weekly Paclitaxel + Carboplatin for Recurrent or Metastatic Head and Neck Squamous Cell Cancer (HNSCC) |
| Eric Sherman, MD | Memorial Sloan Kettering Cancer Center | Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer |
| Sandhya Srinivas, MD | Stanford Cancer Institute | Using Temsirolimus, an mTOR Inhibitor, to Reverse Androgen Insensitivity in Patients with Castration-Resistant Prostate Cancer |
| Furhan Yunus, MD, FACP | University of Tennessee Cancer Institute | A Phase I/II Trial of the Combination of Cisplatin, Cetuximab, and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck |
Tivozanib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Susana Campos, MS, MD, MPH | Dana-Farber/Brigham and Women's Cancer Center | Platinum Sensitive Ovarian Cancer: The Use of Tivozanib as Maintenance Therapy Post Chemotherapy in Patients with Platinum Sensitive Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma |
| Elizabeth Gerstner, MD | Massachusetts General Hospital Cancer Center | Phase II Trial of Tivozanib in Patients with Recurrent Glioblastoma |
| Renuka Iyer, MD | Roswell Park Comprehensive Cancer Center | Multicenter Phase 1b/2 Study of Tivozanib in Patients with Advanced Inoperable Hepatocellular Carcinoma |
| M. Dror Michaelson, MD, PhD | Massachusetts General Hospital Cancer Center | Phase 2 Combination Trial of Tivozanib and Enzalutamide in Men with Advanced Prostate Cancer |
| Daniela Elena Matei, MD | Robert H. Lurie Comprehensive Cancer Center of Northwestern University | The Efficacy and Safety of Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
Trametinib Multi-site Clinical Study
| COORDINATING CENTER/PROJECT CHAIR | PARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR | STUDY |
|---|---|---|
| Douglas Johnson, MD | Vanderbilt-Ingram Cancer Center | A Phase II Open-Label, Two-Arm Study of the MEK Inhibitor, Trametinib, To Investigate the Safety and Anti-Cancer Activity in Subjects with Melanoma with BRAF non-V600 Mutations |
| The University of Texas MD Anderson Cancer Center/Michael Davies, MD, PhD | ||
| Massachusetts General Hospital Cancer Center/Keith Flaherty, MD | ||
| PARTICIPATING NON-MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR | ||
| Georgetown University/ Suthee Rapisuwon, MD |
Trametinib Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Douglas Adkins, MD | Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine | A Phase II Window of Opportunity Trial with GSK1120212 in Surgically Resectable Oral Squamous Cell Cancer |
| Kristen Keon Ciombor, MD | The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute | Randomized Phase II Trial of Single Agent MEK Inhibitor GSK1120212 vs 5-fluorouracil or capecitabine in refractory advanced biliary cancer |
| Adil Daud, MD/ Paul Chapman, MD | UCSF Helen Diller Family Comprehensive Cancer Center/ Memorial Sloan Kettering Cancer Center | Phase I/II Trial of the MEK Inhibitor GSK1120212 + PI3Kinase Inhibitor GSK 2126458 in BRAF Wild Type Melanoma (with or without NRAS mutation) |
| Ursula Matulonis, MD | Dana-Farber/Brigham and Women's Cancer Center | A Single Arm, Single Stage Phase II Open Label Trial of GSK1120212 and GSK2126458 in Persistent or Recurrent Cervical Cancer |
| Terence Williams, MD, PhD | The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute | A Phase I Trial of MEK Inhibitor GSK1120212 in Combination with Neoadjuvant 5-Fluorouracil Chemoradiation in the Treatment of KRAS, BRAF, and NRAS-Mutant Rectal Cancers |
Trifluridine/Tipiracil Studies
| COORDINATING CENTER/PROJECT CHAIR | PARTICIPATING MEMBER INSTITUTION/PRINCIPAL INVESTIGATOR | STUDY |
|---|---|---|
| Christos Fountzilas, MD | Roswell Park Comprehensive Cancer Center | A Phase II Study of TAS-102, Irinotecan and Bevacizumab in Pre-treated Metastatic Colorectal Cancer (TABAsCO) |
| Amit Mahipal, MBBS, MPH | Mayo Clinic | Phase II Trial of Trifluridine/Tipiracil in Combination with Irinotecan in Biliary Tract Cancers |
| Sarbajit Mukherjee, MD, MS | Roswell Park Comprehensive Cancer Center | Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy in Resectable Esophageal and Gastroesophageal junction (GEJ) Adenocarcinoma |
Vorinostat Studies
| INVESTIGATOR | MEMBER INSTITUTION | STUDY |
|---|---|---|
| Emily Chan, MD, PhD | Vanderbilt-Ingram Cancer Center | Phase I Trial of Chemoradiation with Capecitabine and Vorinostat in Pancreatic Cancer |
| Griffith Harsh, MD/Mary Pinder-Schenck, MD | Stanford Cancer Institute/Moffit Cancer Center | Phase I Trial of Vorinostat Concurrent with Stereotactic Radiotherapy in Treatment of Brain Metastases from Non-Small Cell Lung Cancer |
| Ranee Mehra, MD | Fox Chase Cancer Center | Phase I Study of the HDAC Inhibitor Vorinostat with Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC) |
| Theodoros N. Teknos, MD | The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute | A Phase I Trial of Vorinostat in the Treatment of Advanced Oropharyngeal Carcinoma of the Head and Neck |